Skip to content

Study · In vitro (cells) · 2026

3 results

PRPS1 (p.V42L) Mutation in Arts Syndrome Induces Aberrant Neural Stem Cell Development and Neuronal Senescence-Like Phenotype: Rescue by Nicotinamide Mononucleotide Supplementation.

Kim JH, Park SJ, Lee JA, Cheon CK

International journal of stem cells6 Mar 2026

PMID41787648 (opens in a new tab)PMCIDPMC13218841 (opens in a new tab)DOI10.15283/ijsc25127 (opens in a new tab)PepBankPUB-41787648
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    In patient-derived cells, NMN partially ameliorated impaired neural stem cell proliferation.

    In plain wordsIn cells, NMN partly improved impaired neural stem cell growth.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseNSC proliferation
    Study

    humann: not reported in source

    Patient-derived neural stem cells and neurons with PRPS1 p.V42L
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Notably, supplementation with nicotinamide mononucleotide, a precursor of nicotinamide adenine dinucleotide (NAD＋), partially ameliorated defects in NSC proliferation, nuclear architecture, and neuronal morphology.
    1 context sentence
    Summary · context
    In this study, we generated patient-specific induced pluripotent stem cells harboring the PRPS1 p.V42L variant and differentiated them into neural stem cells (NSCs) and neurons to elucidate disease mechanisms and explore potential therapeutic strategies.
  2. 02LabIn vitro (cells)Efficacy outcome

    In patient-derived cells, NMN partially ameliorated nuclear architecture defects.

    In plain wordsIn cells, NMN partly improved abnormal nuclear structure.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    Direction not reportedNuclear architecture
    Study

    humann: not reported in source

    Patient-derived neural stem cells and neurons with PRPS1 p.V42L
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Notably, supplementation with nicotinamide mononucleotide, a precursor of nicotinamide adenine dinucleotide (NAD＋), partially ameliorated defects in NSC proliferation, nuclear architecture, and neuronal morphology.
    1 context sentence
    Summary · context
    In this study, we generated patient-specific induced pluripotent stem cells harboring the PRPS1 p.V42L variant and differentiated them into neural stem cells (NSCs) and neurons to elucidate disease mechanisms and explore potential therapeutic strategies.
  3. 03LabIn vitro (cells)Efficacy outcome

    In patient-derived neurons, NMN partially ameliorated morphological defects.

    In plain wordsIn cells, NMN partly improved abnormal neuron shape.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    Direction not reportedNeuronal morphology
    Study

    humann: not reported in source

    Patient-derived neural stem cells and neurons with PRPS1 p.V42L
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Notably, supplementation with nicotinamide mononucleotide, a precursor of nicotinamide adenine dinucleotide (NAD＋), partially ameliorated defects in NSC proliferation, nuclear architecture, and neuronal morphology.
    1 context sentence
    Summary · context
    In this study, we generated patient-specific induced pluripotent stem cells harboring the PRPS1 p.V42L variant and differentiated them into neural stem cells (NSCs) and neurons to elucidate disease mechanisms and explore potential therapeutic strategies.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.